Patents Examined by Janet L. Andres
  • Patent number: 10729762
    Abstract: This disclosure relates to recombinant bacteria, e.g. L. lactis, expressing heterologous pili containing human immunodeficiency virus (HIV) antigens. In certain embodiments, the recombinant bacteria are administered in combination with other HIV antigens, nucleic acids encoding HIV antigens, recombinant virus encoding HIV antigens, anti-viral agents and/or adjuvants in an effective amount to elicit a mucosal immune response against HIV.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: August 4, 2020
    Assignee: Emory University
    Inventors: Rama Rao Amara, June Scott, Bernard Quigley, Venkateswarlu Chamcha
  • Patent number: 10729754
    Abstract: Methods of treating a patient with human immunodeficiency virus are disclosed. The method includes a providing intradermal and intravenous doses of a aTh1 composition that can increase the CD4+ cells in a patient that are resistant to HIV. The description includes a method for viral load reduction and a viral purge method. The regimen leads to a spike in the viral load and a then a return to baseline or lower levels of the virus and can lead to reduction and/or elimination of the latent viral reservoirs. Kits configured to provide intradermal doses and intravenous doses according to the regimen are also included.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: August 4, 2020
    Assignee: MIRROR BIOLOGICS, INC.
    Inventor: Michael Har-Noy
  • Patent number: 10725056
    Abstract: The present invention relates to metabolic biomarker sets for assessing HIV. In preferred embodiments, the present invention relates to the use of biomarker sets for screening and/or diagnosing HIV infection, for prediction of immunologic response of a mammalian subject to antiretroviral therapy and/or prognosis of HIV disease progression, and for monitoring of HIV disease activity in a mammalian subject. In other embodiments, the invention relates to methods for screening and/or diagnosing HIV infection, for prediction of immunologic response of a mammalian subject to antiretroviral therapy and/or prognosis of HIV disease progression, and for monitoring of HIV disease activity in a mammalian subject, as well as to a kit adapted to carry out the methods. By employing the specific biomarkers and the method according to the present invention it becomes possible to more properly and reliably assess HIV.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: July 28, 2020
    Assignees: BIOCRATES LIFE SCIENCES AG, IDCGS CLINICA DE DIAGNOSTICOS MEDICOS, CENTRO DE GENOMAS
    Inventors: Ismael Dale Cotrim Guerreiro Da Silva, Edson Guimaraes Loturco, Ricoardo Soubie Diaz, Therese Koal
  • Patent number: 10717778
    Abstract: The invention is directed to bispecific molecules comprising an HIV-1 envelope targeting arm and an arm targeting an effector cell, compositions comprising these bispecific molecules and methods of use. In certain aspects, the bispecific molecules of the present invention can bind to two different targets or epitopes on two different cells wherein the first epitope is expressed on a different cell type than the second epitope, such that the bispecific molecules can bring the two cells together. In certain aspects, the bispecific molecules of the present invention can bind to two different cells, wherein the bispecific molecules comprises an arm with the binding specificity of A32, 7B2, CH27, CH28, or CH44.
    Type: Grant
    Filed: September 29, 2015
    Date of Patent: July 21, 2020
    Assignees: DUKE UNIVERSITY, MACROGENICS, INC., THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
    Inventors: Barton F. Haynes, Guido Ferrari, Scott Koenig, Leslie S. Johnson, Chia-Ying Kao Lam, Julia A. Sung, David M. Margolis, Liqin Liu, Jeffrey Lee Nordstrom
  • Patent number: 10690668
    Abstract: The invention provides methods of detection and monitoring of polyomavirus reactivation and active polyomavirus infections using a biological fluid sample. Also provided are methods of risk assessment and risk monitoring of developing a polyomavirus-associated disease.
    Type: Grant
    Filed: January 29, 2013
    Date of Patent: June 23, 2020
    Assignee: Temple University—Of The Commonwealth System Of Higher Education
    Inventors: Kamel Khalili, Ilker K. Sariyer
  • Patent number: 10676521
    Abstract: The present invention relates to methods and agents for preventing the establishment of HIV-1 latent reservoirs or for reducing the size of the reservoirs. Specifically, the disclosure provides methods and agents for preventing the establishment of HIV-1 latent reservoirs or for reducing the size of the reservoirs, the methods comprising administering to the subject a therapeutically effective amount of an isolated anti-HIV antibody, and administering to the subject two or more viral transcription inducers in effective amounts to induce transcription of an HIV provirus in the cells. Further provided are antibodies and viral transcription inducers used in the methods.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: June 9, 2020
    Assignee: The Rockefeller University
    Inventors: Michel Nussenzweig, Ariel Halper-Stromberg, Ching-Lan Lu
  • Patent number: 10670599
    Abstract: The present invention provides combinations of specific binding proteins, such as immunoglobulins, that are designed to be true combinations, essentially all components of the combination being functional and compatible with each other. The invention further provides a method for producing a composition comprising at least two different proteinaceous molecules comprising paired variable regions, the at least two proteinaceous molecules having different binding specificities, comprising paired variable regions, at least two proteinaceous molecules having different binding specificities, comprising contacting at least three different variable regions under conditions allowing for pairing of variable regions and harvesting essentially all proteinaceous molecules having binding specificities resulting from the pairing.
    Type: Grant
    Filed: August 21, 2017
    Date of Patent: June 2, 2020
    Assignee: Merus N.V.
    Inventors: Hendricus Renerus Jacobus Mattheus Hoogenboom, Ton Logtenberg
  • Patent number: 10663468
    Abstract: This invention relates to high throughput methods of determining a viral titer. The instant invention addresses the need for a more rapid and cost effective method of quantitating infectious viral particles in a sample.
    Type: Grant
    Filed: July 20, 2016
    Date of Patent: May 26, 2020
    Assignee: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.
    Inventor: Jean Reyes
  • Patent number: 10590394
    Abstract: A method of non-covalently loading a plant picornavirus is described. The method includes contacting a plant picornavirus in solution with a molar excess of a cargo molecule to load the plant picornavirus with the cargo molecule, and then purifying the loaded plant picornavirus. Examples of cargo molecules include imaging agents, antitumor agents, and antiviral agents. Loaded plant picornaviruses prepared in this manner can be used to delivering cargo molecule to cells.
    Type: Grant
    Filed: February 18, 2014
    Date of Patent: March 17, 2020
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Nicole Steinmetz, Daniel Popkin
  • Patent number: 10472412
    Abstract: The invention provides a construct comprising two or more fusion proteins of Formulas (I)-(IV): A-(optional linker)-C-(optional linker)-B (Formula I), B-(optional linker)-D-(optional linker)-E-(optional linker)-B (Formula II), A-(optional linker)-C (Formula III), and B-(optional linker)-D-(optional linker)-E (Formula IV), wherein A denotes an antibody or antibody fragment, B denotes a single domain CD4, C denotes an immunoglobulin light chain constant region D denotes an immunoglobulin heavy chain constant region, and E denotes an Fc region or a portion thereof that is optionally defucosylated.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: November 12, 2019
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Fudan University
    Inventors: Dimiter S. Dimitrov, Weizao Chen, Tianlei Ying
  • Patent number: 10466242
    Abstract: The invention concerns soluble and antigenic HTLV p24 variants that can be fused to chaperones and their use in diagnostic applications such as immunoassays for detecting antibodies against HTLV-I or HTLV-II in an isolated biological sample. In particular, the invention relates to a soluble HTLV-I or HTLV-II p24 antigen comprising either the N- or the C-terminal domain of p24 and lacking the other domain. Moreover, the invention covers recombinant DNA molecules encoding these HTLV-I and -II fusion antigens as well as their recombinant production using expression vectors and host cells transformed with such expression vectors. In addition, the invention focuses on compositions of these HTLV p24 antigens with HTLV gp21 antigen and on an immunoassay method for detection of HTLV antibodies using the antigens of the invention. Also the use of HTLV p24 antigens in an in vitro diagnostic assay as well as a reagent kit for detection of anti-HTLV-antibodies comprising said HTLV antigens is encompassed.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: November 5, 2019
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Elke Faatz, Christian Scholz, Peter Muench
  • Patent number: 10426830
    Abstract: The invention provides methods and compositions for eliciting broad immune responses. The methods employ nucleic acid vaccines that encodes highly conserved elements from a virus.
    Type: Grant
    Filed: August 12, 2016
    Date of Patent: October 1, 2019
    Assignees: THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, UNIVERSITY OF WASHNGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
    Inventors: George Pavlakis, Barbara Felber, James Mullins
  • Patent number: 10426831
    Abstract: The invention provides compositions, methods, and kits for the treatment or prevention of viral infections. The polyvalent (e.g., 2-valent) vaccines described herein incorporate computationally-optimized viral polypeptides that can increase the diversity or breadth and depth of cellular immune response in vaccinated subjects.
    Type: Grant
    Filed: April 17, 2017
    Date of Patent: October 1, 2019
    Assignees: Beth Israel Deaconess Medical Center, Inc., TRIAD NATIONAL SECURITY, LLC
    Inventors: Dan H. Barouch, Bette T. Korber, William M. Fischer
  • Patent number: 10408836
    Abstract: Provided herein is a method of detecting the presence of influenza virus in a sample while minimizing false positives due to presence of one or more other pathogens in the sample, the method including measuring the enzymatic activity of neuraminidase (NA) in the sample under one or more differentiating conditions selected from the group consisting of pH, binding to anti-NanA antibody, size exclusion, hemagglutinin (HA) binding, chemical inhibition, and combinations thereof.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: September 10, 2019
    Assignees: University of Cincinnati, MicrobeCapture, LLC
    Inventors: Alison A. Weiss, Karen Melissa Gallegos Villalobos, David Ralph
  • Patent number: 10369171
    Abstract: The present invention relates to methods for killing neoplastic cells, such as ras-activated cancerous cells, in vitro. In particular embodiments, an attenuated reovirus (e.g., a reovirus lacking a wild-type S1 gene) may be administered to a mixed cellular composition comprising cancerous cells and stem cells such as adult stem cells and/or hematopoietic stem cells; in these embodiments, the attenuated reovirus may result in killing of the cancerous cells with little or no damage to the healthy stem cells.
    Type: Grant
    Filed: March 12, 2008
    Date of Patent: August 6, 2019
    Assignee: VIROCURE, INC.
    Inventors: Manbok Kim, Derrick E. Rancourt, Nicole Zur Nieden, Randal N. Johnston
  • Patent number: 10358683
    Abstract: The present invention provides methods and compositions for determining whether a subject would benefit from co-receptor inhibitor therapy. In certain aspects, the methods can be used to determine whether a subject infected with a dual-mixed tropic population of HIV would benefit from CCCR5-inhibitor therapy or CXCR4-inhibitor therapy, the methods comprising determining whether the HIV population is a homogeneous or heterogeneous population of HIV, wherein the nature of the homogenous or heterogenous population of HIV indicates whether the patient would benefit from co-receptor inhibitor therapy.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: July 23, 2019
    Assignee: Laboratory Corporation of America Holdings
    Inventors: Wei Huang, Signe Fransen, Christos Petropoulos, Jonathan Toma, Jeannette Whitcomb
  • Patent number: 10329583
    Abstract: The present invention relates to recombinant viral vectors and methods of using the recombinant viral vectors to induce an immune response to influenza A viruses. The invention provides recombinant viral vectors based, for example, on the non-replicating modified vaccinia virus Ankara. When administered according to methods of the invention, the recombinant viral vectors are designed to be cross-protective and induce heterosubtypic immunity to influenza A viruses.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: June 25, 2019
    Assignee: OLOGY BIOSERVICES INC.
    Inventors: Falko-Günter Falkner, Birgit Schafer, P Noel Barrett, Thomas R. Kreil, Hartmut Ehrlich, Annett Hessel
  • Patent number: 10322172
    Abstract: A live, attenuated HIV vaccine is provided, and methods of making a attenuated HIV vaccine are provided.
    Type: Grant
    Filed: February 10, 2015
    Date of Patent: June 18, 2019
    Assignee: NUtech Ventures
    Inventors: Jiantao Guo, Qingsheng Li, Wei Niu, Yue Li, Nanxi Wang
  • Patent number: 10316066
    Abstract: The present invention is directed to a dengue virus chimeric polyepitope composed of fragments of non-structural proteins and its use in an immunogenic composition against dengue virus infection. The present invention provides means, in particular polynucleotides, vectors, cells and methods to produce vectors expressing said chimeric polyepitopes, in particular vectors consisting of recombinant measles virus (MV) particles. The present invention also relates to the use of the recombinant MV particles, in particular under the form of a composition or of a vaccine, for the prevention and/or treatment of a dengue virus infection.
    Type: Grant
    Filed: June 22, 2015
    Date of Patent: June 11, 2019
    Assignees: INSTITUT PASTEUR, INSTITUT PASTEUR DU CAMBODGE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Frederic Tangy, Anavaj Shakuntabai, Etienne Simon-Loriere, Claude Roth, Philippe Buchy
  • Patent number: 10316295
    Abstract: Provided are modified virus-like particles (VLPs) of paramyxoviruses, compositions containing them, methods of using the VLPs for delivery of any particular protein of interest to any of a variety of cells, kits that contain expression vectors for making, using and detecting VLPs, and methods for screening for anti-viral compounds using the VLPs. The modified VLPs contain a contiguous recombinant polypeptide that contains i) all or a segment of a C-terminal domain of a paramyxovirus nucleocapsid protein and ii) a polypeptide sequence of a distinct protein. Non-covalent complexes of paramyxovirus M protein and fusion proteins that contain a C-terminal domain of a paramyxovirus nucleocapsid protein and a polypeptide sequence of a distinct protein are provided, as are non-covalent complexes of cells, and cell receptors, with modified VLPs.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: June 11, 2019
    Assignee: The Penn State Research Foundation
    Inventors: Anthony Paul Schmitt, Phuong Tieu Schmitt, Greeshma Vivekananda Ray